dofequidar has been researched along with Leukemia, Lymphocytic, Chronic, B-Cell in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirano, I; Kiyoi, H; Maekawa, M; Matsui, H; Nakamura, S; Naoe, T; Ohnishi, K; Ohno, R; Ono, T; Shigeno, K; Shinjo, K; Sugimoto, Y; Takeshita, A; Tobita, T; Yamakage, N | 1 |
1 other study(ies) available for dofequidar and Leukemia, Lymphocytic, Chronic, B-Cell
| Article | Year |
|---|---|
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Count; Cell Line, Transformed; Cell Line, Tumor; Cyclosporins; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Immunosuppressive Agents; Inotuzumab Ozogamicin; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Quinolines; Sialic Acid Binding Ig-like Lectin 2; Treatment Outcome; Tumor Cells, Cultured | 2009 |